Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer
29 Enero 2024 - 7:00AM
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage
company that aims to establish gene therapy as a new standard of
care for highly prevalent ocular diseases, today announced that
Romuald “Romu” Corbau, Ph.D., has joined Adverum as the company’s
chief scientific officer. Dr. Corbau will serve as a member of
Adverum’s executive committee.
“On behalf of the entire team at Adverum, I am delighted to
welcome Dr. Corbau as the newest member of our executive leadership
team. Romu has spent the majority of his career working to deliver
on the promise of gene therapy. Earlier in his career, Romu led
Spark Therapeutics’ translational R&D for Luxturna®, a
subretinal injection gene therapy product for Leber’s congenital
amaurosis, an inherited form of vision loss that frequently results
in blindness,” stated Laurent Fischer, M.D., president and chief
executive officer of Adverum. “We expect that Romu’s deep expertise
in AAV-mediated gene therapies and ophthalmic research will prove
invaluable as we advance Ixo-vec toward pivotal trials and
commercialization for the treatment of wet AMD, the leading cause
of blindness in the elderly.”
“I am thrilled to head up the team responsible for Adverum’s
industry-leading efforts in AAV vector and cassette optimization
and excited to advance our early-stage research assets into our
development pipeline,” commented Dr. Corbau. “This is an exciting
time to join Adverum, as we look forward to multiple expected
near-term data readouts from the ongoing LUNA Phase 2 clinical
trial of Ixo-vec in wet AMD. I am excited to be part of advancing
Ixo-vec with the goal of ultimately providing patients with what I
believe has the potential to be the leading, and truly
transformative, once-and-done wet AMD therapy.”
Dr. Corbau has over 25 years of industry experience ranging from
startups to global pharmaceutical companies in the United States
and Europe. Dr. Corbau joins Adverum from GenEdit, where he served
as Chief Scientific Officer. Prior to joining GenEdit, Dr. Corbau
progressed from Vice President of Research to Chief Scientific
Officer at Freeline, a clinical stage company developing AAV-vector
mediated systemic gene therapies for chronic diseases. Prior to
Freeline, Dr. Corbau was Translational Lead at Spark Therapeutics,
where his Translational department was focused on AAV sub-retinal
injection gene therapy approaches for ocular indications, as well
as Spark Therapeutics’ CNS and systemic, liver-directed therapies.
Before joining Spark Therapeutics, Dr. Corbau held various research
positions at Pfizer in the UK, CISTIM (The Centre for Innovation
and Stimulation of Drug Discovery) in Belgium, and Children’s
Hospital of Philadelphia. Dr. Corbau earned his M.A. in
Biochemistry from Lille University and his Ph.D. from L'Institut
national de la santé et de la recherche médicale (INSERM) in
Heidelberg, Germany.
Inducement GrantOn January 22, 2024, the
company granted Dr. Corbau a stock option to purchase 600,000
shares of Adverum’s common stock pursuant to the inducement grant
exception under Nasdaq Rule 5635(c)(4), as an inducement that is
material to his entering into employment with Adverum. The option
has a per-share exercise price equal to the closing sales price of
Adverum’s common stock on the Nasdaq Stock Market on the grant
date, and will vest over four years, subject to his continued
service with Adverum.
About Adverum BiotechnologiesAdverum
Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that
aims to establish gene therapy as a new standard of care for highly
prevalent ocular diseases with the aspiration of developing
functional cures to restore vision and prevent blindness.
Leveraging the capabilities of its proprietary intravitreal (IVT)
platform, Adverum is developing durable, single-administration
therapies, designed to be delivered in physicians’ offices, to
eliminate the need for frequent ocular injections to treat these
diseases. Adverum is evaluating its novel gene therapy candidate,
ixoberogene soroparvovec (Ixo-vec, formerly referred to as
ADVM-022), as a one-time, IVT injection for patients with
neovascular or wet age-related macular degeneration. Additionally,
by overcoming the challenges associated with current treatment
paradigms for debilitating ocular diseases, Adverum aspires to
transform the standard of care, preserve vision, and create a
profound societal impact around the globe. For more information,
please visit www.adverum.com.
Forward-looking Statements Statements contained
in this press release regarding events or results that may occur in
the future are “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995. Such
statements include but are not limited to statements regarding Dr.
Corbau’s expected contributions to Adverum, Adverum’s continued
pipeline development and Ixo-vec’s potential to be the leading and
truly transformative one-and-done wet AMD therapy. Actual results
could differ materially from those anticipated in such
forward-looking statements as a result of various risks and
uncertainties, including risks inherent to, without limitation:
Adverum’s novel technology, which makes it difficult to predict the
timing of commencement and completion of clinical trials;
regulatory uncertainties; enrollment uncertainties; the results of
early clinical trials not always being predictive of future
clinical trials and results; and the potential for future
complications or side effects in connection with use of Ixo-vec.
Additional risks and uncertainties facing Adverum are set forth
under the caption “Risk Factors” and elsewhere in Adverum’s
Securities and Exchange Commission (SEC) filings and reports,
including Adverum’s Quarterly Report on Form 10-Q for the quarter
ended September 30, 2023 filed with the SEC on November 9, 2023.
All forward-looking statements contained in this press release
speak only as of the date on which they were made. Adverum
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made, except as required by law.
Inquiries:Adverum Investor
RelationsEmail: ir@adverum.com
Adverum Biotechnologies (NASDAQ:ADVM)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Adverum Biotechnologies (NASDAQ:ADVM)
Gráfica de Acción Histórica
De May 2023 a May 2024